Sample size reassessment for a two-stage design controlling the false discovery rate

被引:4
|
作者
Zehetmayer, Sonja [1 ]
Graf, Alexandra C. [1 ]
Posch, Martin [1 ]
机构
[1] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
基金
奥地利科学基金会;
关键词
adaptive design; false discovery rate; high-dimensional data; two-stage design; TYPE-1 ERROR RATE; GENE-EXPRESSION; CLINICAL-TRIALS; LARGE NUMBER; ARRAY DATA; POWER; INFLATION;
D O I
10.1515/sagmb-2014-0025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sample size calculations for gene expression microarray and NGS-RNA-Seq experiments are challenging because the overall power depends on unknown quantities as the proportion of true null hypotheses and the distribution of the effect sizes under the alternative. We propose a two-stage design with an adaptive interim analysis where these quantities are estimated from the interim data. The second stage sample size is chosen based on these estimates to achieve a specific overall power. The proposed procedure controls the power in all considered scenarios except for very low first stage sample sizes. The false discovery rate (FDR) is controlled despite of the data dependent choice of sample size. The two-stage design can be a useful tool to determine the sample size of high-dimensional studies if in the planning phase there is high uncertainty regarding the expected effect sizes and variability.
引用
收藏
页码:429 / 442
页数:14
相关论文
共 50 条
  • [41] Two-stage phase II survival trial design
    Wu, Jianrong
    Chen, Li
    Wei, Jing
    Weiss, Heidi
    Chauhan, Aman
    PHARMACEUTICAL STATISTICS, 2020, 19 (03) : 214 - 229
  • [42] An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies
    Vangelis Karalis
    Panos Macheras
    Pharmaceutical Research, 2013, 30 : 1824 - 1835
  • [43] Sources of variation in false discovery rate estimation include sample size, correlation, and inherent differences between groups
    Jiexin Zhang
    Kevin R Coombes
    BMC Bioinformatics, 13
  • [44] Performance of two-stage continual reassessment method relative to an optimal benchmark
    Wages, Nolan A.
    Conaway, Mark R.
    O'Quigley, John
    CLINICAL TRIALS, 2013, 10 (06) : 862 - 875
  • [45] Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation
    Franz Koenig
    Martin Wolfsegger
    Thomas Jaki
    Helmut Schütz
    Gernot Wassmer
    Trials, 16
  • [46] Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation
    Koenig, Franz
    Wolfsegger, Martin
    Jaki, Thomas
    Schuetz, Helmut
    Wassmer, Gernot
    TRIALS, 2015, 16
  • [47] Sample size re-estimation for confirmatory two-stage flexible multi-arm trial with normal outcomes
    Li, Yan
    Wang, Guoqiao
    Szychowski, Jeff M.
    JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION, 2020, 90 (01) : 157 - 178
  • [48] A two-stage design for bridging studies
    Hsiao, CF
    Xu, JZ
    Liu, JP
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (01) : 75 - 83
  • [49] Adapting to one- and two-way classified structures of hypotheses while controlling the false discovery rate
    Nandi, Shinjini
    Sarkar, Sanat K.
    Chen, Xiongzhi
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2021, 215 : 95 - 108
  • [50] An investigation of two multivariate permutation methods for controlling the false discovery proportion
    Korn, Edward L.
    Li, Ming-Chung
    McShane, Lisa M.
    Simon, Richard
    STATISTICS IN MEDICINE, 2007, 26 (24) : 4428 - 4440